A randomized phase 2 study of immunotherapy drug, bevacizumab, in combination with either a weekly antibody drug conjugate, anetumab ravtansine, or weekly chemotherapy drug in platinum-resistant or platinum refractory ovarian, fallopian tube, or primary peritoneal cancer

UVA Tracking #
HSR200252
Principal Investigator
Linda R Duska
Contact
Benjamin Prabhu
Contact Email
Contact Phone
434.297.4980
Official Trial Title
A randomized phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer
Study Description

The UVA Cancer Center has a clinical trial for women ages 18 and over who have platinum-resistant or platinum refractory ovarian cancer, high grade serous or high grade endometroid ovarian, fallopian tube, or primary peritoneal cancer. To participate, you must have already been treated with platinum-based chemotherapy and your disease has now become resistant to this type of treatment.
Efficacy and the side effects of the two treatments (bevacizumab with anetumab ravtansine vs. bevacizumab with the chemotherapy drug, paclitaxel) will be studied. For those receiving anetumab ravtansine, the amount of time the drug remains in your system and if you develop any anti-bodies to it will also be evaluated. Participants will not be able to choose which combination of treatment they will be receiving.
The overall trial does not have a set duration, study treatment will continue for as long are your study doctor thinks the medicine is helping you.
If eligible and you choose to take part in this clinical trial, the bevacizumab and/or anetumab ravtansine will be supplied at no charge while you take part in this study. The cost of administering the bevacizumab and/or anetumab ravtansine is not paid by the study sponsor and will be billed to you or your insurance. You (or your insurance company) will be responsible for all of the other costs of treating your cancer while in this study, including the cost of tests, procedures, or medicines to manage any side effects. If you are assigned to receive paclitaxel, your health plan/insurance company will need to cover this cost.
Additional information can be found here: NCT03587311